Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma
BACKGROUND During radiolabeled metaiodobenzylguanidine (MIBG) administration in children with neuroblastoma, the thyroid is protected from 123/131I uptake by potassium iodide. Despite this protection, up to 64% of patients develop thyroid dysfunction. The authors introduce a new method of radiation...
Gespeichert in:
| Veröffentlicht in: | Cancer 2003-07, Vol.98 (2), p.389-396 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 396 |
|---|---|
| container_issue | 2 |
| container_start_page | 389 |
| container_title | Cancer |
| container_volume | 98 |
| creator | van Santen, Hanneke M. de Kraker, Jan van Eck, Berthe L. F. de Vijlder, Jan J. M. Vulsma, Thomas |
| description | BACKGROUND
During radiolabeled metaiodobenzylguanidine (MIBG) administration in children with neuroblastoma, the thyroid is protected from 123/131I uptake by potassium iodide. Despite this protection, up to 64% of patients develop thyroid dysfunction. The authors introduce a new method of radiation protection for the thyroid gland.
METHODS
In a prospective cohort study, 34 children with neuroblastoma who received MIBG were given thyroxine, methimazole, and potassium iodide for protection of the thyroid gland. Protection started 1 day before the start of diagnostic 123I‐MIBG and was continued until 4 weeks after the last therapeutic 131I‐MIBG dose. Follow‐up measurements were performed every 3 months after the protection was stopped. Visualization of the thyroid on MIBG images was reviewed by three nuclear medicine physicians. Results were compared with a historic control group of children who had received potassium iodide for thyroid protection during MIBG administration.
RESULTS
After a mean follow‐up of 19 months, there were 23 evaluable patients. Thyroid function was normal in 86% of survivors compared with 44% of children in the historic control group (P = 0.011; Pearson chi‐square test). Scintigraphic visualization of the thyroid diminished substantially after the new protection (21.5% vs. 5.3%, respectively; P = 0.000).
CONCLUSIONS
The results of the current study indicate that compared with potassium iodide alone, combined thyroxine, methimazole, and potassium iodide protect the thyroid more effectively against radiation damage from 123/131I during diagnostic and therapeutic MIBG administration in children with neuroblastoma. Cancer 2003;98:389–96. © 2003 American Cancer Society.
DOI 10.1002/cncr.11523
A new protective regimen against radiation damage to the thyroid gland during treatment with radiolabeled metaiodobenzylguanidine in children with neuroblastoma is introduced. This regimen uses combined thyroxine, methimazole, and potassium iodide. |
| doi_str_mv | 10.1002/cncr.11523 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_cncr_11523</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CNCR11523</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3913-37d9f3082be7f4971f7327e3128d56e613beab81e8b0209330372f4733a886523</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi0EotvChR-AfOGCSPFHsk6OaMVHpQokBBK3aGJPdo0cO7IT2u2_5B_hbFbqjYM1ntGj9x3NS8grzq45Y-K99jpec14J-YRsOGtUwXgpnpINY6wuqlL-uiCXKf3OrRKVfE4uuKiVkFu-IX9vhjGGP2hoBGNhssHTPJhQn76hp9MB8zvGYA3dO_CG3tnpsI7urcd3dMDpYAd4CC43CzCGCVKy80BtMNYgNXO0fk-zwd6HNFl9wrJyhBHnpZ8TLmbLEsFBhy5vlHUhC4QO_cPR7Wfw1mRDaj3VB-tMRL_u4nGOoXOQpjDAC_KsB5fw5blekZ-fPv7YfSluv32-2X24LbRsuCykMk0vWS06VH3ZKN4rKRTKfBpTbXHLZYfQ1RzrjgnWSMmkEn2ppIS63uZbX5G3q66OIaWIfTvGfIV4bDlrl1zaJZf2lEuGX6_wOHcDmkf0HEQG3pwBSBpcH8Frmx65silF1VSZ4yt3Zx0e_2PZ7r7uvq_m_wDKhKuD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>van Santen, Hanneke M. ; de Kraker, Jan ; van Eck, Berthe L. F. ; de Vijlder, Jan J. M. ; Vulsma, Thomas</creator><creatorcontrib>van Santen, Hanneke M. ; de Kraker, Jan ; van Eck, Berthe L. F. ; de Vijlder, Jan J. M. ; Vulsma, Thomas</creatorcontrib><description>BACKGROUND
During radiolabeled metaiodobenzylguanidine (MIBG) administration in children with neuroblastoma, the thyroid is protected from 123/131I uptake by potassium iodide. Despite this protection, up to 64% of patients develop thyroid dysfunction. The authors introduce a new method of radiation protection for the thyroid gland.
METHODS
In a prospective cohort study, 34 children with neuroblastoma who received MIBG were given thyroxine, methimazole, and potassium iodide for protection of the thyroid gland. Protection started 1 day before the start of diagnostic 123I‐MIBG and was continued until 4 weeks after the last therapeutic 131I‐MIBG dose. Follow‐up measurements were performed every 3 months after the protection was stopped. Visualization of the thyroid on MIBG images was reviewed by three nuclear medicine physicians. Results were compared with a historic control group of children who had received potassium iodide for thyroid protection during MIBG administration.
RESULTS
After a mean follow‐up of 19 months, there were 23 evaluable patients. Thyroid function was normal in 86% of survivors compared with 44% of children in the historic control group (P = 0.011; Pearson chi‐square test). Scintigraphic visualization of the thyroid diminished substantially after the new protection (21.5% vs. 5.3%, respectively; P = 0.000).
CONCLUSIONS
The results of the current study indicate that compared with potassium iodide alone, combined thyroxine, methimazole, and potassium iodide protect the thyroid more effectively against radiation damage from 123/131I during diagnostic and therapeutic MIBG administration in children with neuroblastoma. Cancer 2003;98:389–96. © 2003 American Cancer Society.
DOI 10.1002/cncr.11523
A new protective regimen against radiation damage to the thyroid gland during treatment with radiolabeled metaiodobenzylguanidine in children with neuroblastoma is introduced. This regimen uses combined thyroxine, methimazole, and potassium iodide.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.11523</identifier><identifier>PMID: 12872361</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>3-Iodobenzylguanidine - adverse effects ; 3-Iodobenzylguanidine - therapeutic use ; 3‐iodobenzylguanidine ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Child ; Child, Preschool ; Diseases of the nervous system ; Female ; Humans ; hypothyroidism ; Infant ; Investigative techniques, diagnostic techniques (general aspects) ; Male ; Medical sciences ; Methimazole - therapeutic use ; Nervous system ; neuroblastoma ; Neuroblastoma - radiotherapy ; Potassium Iodide - therapeutic use ; radiation damage ; radiation protection ; Radiation-Protective Agents - therapeutic use ; Radionuclide investigations ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; Thyroid Diseases - etiology ; Thyroid Diseases - prevention & control ; Thyroid Function Tests ; thyroid gland ; Thyroxine - therapeutic use ; Treatment Outcome</subject><ispartof>Cancer, 2003-07, Vol.98 (2), p.389-396</ispartof><rights>Copyright © 2003 American Cancer Society</rights><rights>2003 INIST-CNRS</rights><rights>Copyright 2003 American Cancer Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3913-37d9f3082be7f4971f7327e3128d56e613beab81e8b0209330372f4733a886523</citedby><cites>FETCH-LOGICAL-c3913-37d9f3082be7f4971f7327e3128d56e613beab81e8b0209330372f4733a886523</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.11523$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.11523$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14942595$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12872361$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Santen, Hanneke M.</creatorcontrib><creatorcontrib>de Kraker, Jan</creatorcontrib><creatorcontrib>van Eck, Berthe L. F.</creatorcontrib><creatorcontrib>de Vijlder, Jan J. M.</creatorcontrib><creatorcontrib>Vulsma, Thomas</creatorcontrib><title>Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND
During radiolabeled metaiodobenzylguanidine (MIBG) administration in children with neuroblastoma, the thyroid is protected from 123/131I uptake by potassium iodide. Despite this protection, up to 64% of patients develop thyroid dysfunction. The authors introduce a new method of radiation protection for the thyroid gland.
METHODS
In a prospective cohort study, 34 children with neuroblastoma who received MIBG were given thyroxine, methimazole, and potassium iodide for protection of the thyroid gland. Protection started 1 day before the start of diagnostic 123I‐MIBG and was continued until 4 weeks after the last therapeutic 131I‐MIBG dose. Follow‐up measurements were performed every 3 months after the protection was stopped. Visualization of the thyroid on MIBG images was reviewed by three nuclear medicine physicians. Results were compared with a historic control group of children who had received potassium iodide for thyroid protection during MIBG administration.
RESULTS
After a mean follow‐up of 19 months, there were 23 evaluable patients. Thyroid function was normal in 86% of survivors compared with 44% of children in the historic control group (P = 0.011; Pearson chi‐square test). Scintigraphic visualization of the thyroid diminished substantially after the new protection (21.5% vs. 5.3%, respectively; P = 0.000).
CONCLUSIONS
The results of the current study indicate that compared with potassium iodide alone, combined thyroxine, methimazole, and potassium iodide protect the thyroid more effectively against radiation damage from 123/131I during diagnostic and therapeutic MIBG administration in children with neuroblastoma. Cancer 2003;98:389–96. © 2003 American Cancer Society.
DOI 10.1002/cncr.11523
A new protective regimen against radiation damage to the thyroid gland during treatment with radiolabeled metaiodobenzylguanidine in children with neuroblastoma is introduced. This regimen uses combined thyroxine, methimazole, and potassium iodide.</description><subject>3-Iodobenzylguanidine - adverse effects</subject><subject>3-Iodobenzylguanidine - therapeutic use</subject><subject>3‐iodobenzylguanidine</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Diseases of the nervous system</subject><subject>Female</subject><subject>Humans</subject><subject>hypothyroidism</subject><subject>Infant</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methimazole - therapeutic use</subject><subject>Nervous system</subject><subject>neuroblastoma</subject><subject>Neuroblastoma - radiotherapy</subject><subject>Potassium Iodide - therapeutic use</subject><subject>radiation damage</subject><subject>radiation protection</subject><subject>Radiation-Protective Agents - therapeutic use</subject><subject>Radionuclide investigations</subject><subject>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</subject><subject>Thyroid Diseases - etiology</subject><subject>Thyroid Diseases - prevention & control</subject><subject>Thyroid Function Tests</subject><subject>thyroid gland</subject><subject>Thyroxine - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1v1DAQhi0EotvChR-AfOGCSPFHsk6OaMVHpQokBBK3aGJPdo0cO7IT2u2_5B_hbFbqjYM1ntGj9x3NS8grzq45Y-K99jpec14J-YRsOGtUwXgpnpINY6wuqlL-uiCXKf3OrRKVfE4uuKiVkFu-IX9vhjGGP2hoBGNhssHTPJhQn76hp9MB8zvGYA3dO_CG3tnpsI7urcd3dMDpYAd4CC43CzCGCVKy80BtMNYgNXO0fk-zwd6HNFl9wrJyhBHnpZ8TLmbLEsFBhy5vlHUhC4QO_cPR7Wfw1mRDaj3VB-tMRL_u4nGOoXOQpjDAC_KsB5fw5blekZ-fPv7YfSluv32-2X24LbRsuCykMk0vWS06VH3ZKN4rKRTKfBpTbXHLZYfQ1RzrjgnWSMmkEn2ppIS63uZbX5G3q66OIaWIfTvGfIV4bDlrl1zaJZf2lEuGX6_wOHcDmkf0HEQG3pwBSBpcH8Frmx65silF1VSZ4yt3Zx0e_2PZ7r7uvq_m_wDKhKuD</recordid><startdate>20030715</startdate><enddate>20030715</enddate><creator>van Santen, Hanneke M.</creator><creator>de Kraker, Jan</creator><creator>van Eck, Berthe L. F.</creator><creator>de Vijlder, Jan J. M.</creator><creator>Vulsma, Thomas</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20030715</creationdate><title>Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma</title><author>van Santen, Hanneke M. ; de Kraker, Jan ; van Eck, Berthe L. F. ; de Vijlder, Jan J. M. ; Vulsma, Thomas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3913-37d9f3082be7f4971f7327e3128d56e613beab81e8b0209330372f4733a886523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>3-Iodobenzylguanidine - adverse effects</topic><topic>3-Iodobenzylguanidine - therapeutic use</topic><topic>3‐iodobenzylguanidine</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Diseases of the nervous system</topic><topic>Female</topic><topic>Humans</topic><topic>hypothyroidism</topic><topic>Infant</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methimazole - therapeutic use</topic><topic>Nervous system</topic><topic>neuroblastoma</topic><topic>Neuroblastoma - radiotherapy</topic><topic>Potassium Iodide - therapeutic use</topic><topic>radiation damage</topic><topic>radiation protection</topic><topic>Radiation-Protective Agents - therapeutic use</topic><topic>Radionuclide investigations</topic><topic>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</topic><topic>Thyroid Diseases - etiology</topic><topic>Thyroid Diseases - prevention & control</topic><topic>Thyroid Function Tests</topic><topic>thyroid gland</topic><topic>Thyroxine - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Santen, Hanneke M.</creatorcontrib><creatorcontrib>de Kraker, Jan</creatorcontrib><creatorcontrib>van Eck, Berthe L. F.</creatorcontrib><creatorcontrib>de Vijlder, Jan J. M.</creatorcontrib><creatorcontrib>Vulsma, Thomas</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Santen, Hanneke M.</au><au>de Kraker, Jan</au><au>van Eck, Berthe L. F.</au><au>de Vijlder, Jan J. M.</au><au>Vulsma, Thomas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2003-07-15</date><risdate>2003</risdate><volume>98</volume><issue>2</issue><spage>389</spage><epage>396</epage><pages>389-396</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND
During radiolabeled metaiodobenzylguanidine (MIBG) administration in children with neuroblastoma, the thyroid is protected from 123/131I uptake by potassium iodide. Despite this protection, up to 64% of patients develop thyroid dysfunction. The authors introduce a new method of radiation protection for the thyroid gland.
METHODS
In a prospective cohort study, 34 children with neuroblastoma who received MIBG were given thyroxine, methimazole, and potassium iodide for protection of the thyroid gland. Protection started 1 day before the start of diagnostic 123I‐MIBG and was continued until 4 weeks after the last therapeutic 131I‐MIBG dose. Follow‐up measurements were performed every 3 months after the protection was stopped. Visualization of the thyroid on MIBG images was reviewed by three nuclear medicine physicians. Results were compared with a historic control group of children who had received potassium iodide for thyroid protection during MIBG administration.
RESULTS
After a mean follow‐up of 19 months, there were 23 evaluable patients. Thyroid function was normal in 86% of survivors compared with 44% of children in the historic control group (P = 0.011; Pearson chi‐square test). Scintigraphic visualization of the thyroid diminished substantially after the new protection (21.5% vs. 5.3%, respectively; P = 0.000).
CONCLUSIONS
The results of the current study indicate that compared with potassium iodide alone, combined thyroxine, methimazole, and potassium iodide protect the thyroid more effectively against radiation damage from 123/131I during diagnostic and therapeutic MIBG administration in children with neuroblastoma. Cancer 2003;98:389–96. © 2003 American Cancer Society.
DOI 10.1002/cncr.11523
A new protective regimen against radiation damage to the thyroid gland during treatment with radiolabeled metaiodobenzylguanidine in children with neuroblastoma is introduced. This regimen uses combined thyroxine, methimazole, and potassium iodide.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>12872361</pmid><doi>10.1002/cncr.11523</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2003-07, Vol.98 (2), p.389-396 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_cncr_11523 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | 3-Iodobenzylguanidine - adverse effects 3-Iodobenzylguanidine - therapeutic use 3‐iodobenzylguanidine Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Child Child, Preschool Diseases of the nervous system Female Humans hypothyroidism Infant Investigative techniques, diagnostic techniques (general aspects) Male Medical sciences Methimazole - therapeutic use Nervous system neuroblastoma Neuroblastoma - radiotherapy Potassium Iodide - therapeutic use radiation damage radiation protection Radiation-Protective Agents - therapeutic use Radionuclide investigations Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) Thyroid Diseases - etiology Thyroid Diseases - prevention & control Thyroid Function Tests thyroid gland Thyroxine - therapeutic use Treatment Outcome |
| title | Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T00%3A37%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improved%20radiation%20protection%20of%20the%20thyroid%20gland%20with%20thyroxine,%20methimazole,%20and%20potassium%20iodide%20during%20diagnostic%20and%20therapeutic%20use%20of%20radiolabeled%20metaiodobenzylguanidine%20in%20children%20with%20neuroblastoma&rft.jtitle=Cancer&rft.au=van%20Santen,%20Hanneke%20M.&rft.date=2003-07-15&rft.volume=98&rft.issue=2&rft.spage=389&rft.epage=396&rft.pages=389-396&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.11523&rft_dat=%3Cwiley_cross%3ECNCR11523%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12872361&rfr_iscdi=true |